Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | PYCR1 | P32322 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11881187 | 0.89 | NR1H2 (0.62) | NR1H2NR1H3TSHRALDH1A1CRHBP | |
| SCHEMBL642317 | 0.85 | CRHBP (0.61) | NR1H2NR1H3TSHRALDH1A1CRHBP | |
| Hydrochloric Acid SCHEMBL27388371 | 0.83 | CRHBP (0.59) | NR1H2NR1H3TSHRALDH1A1CRHBP | |
| SCHEMBL4403042 | 0.82 | NR1H2 (0.56) | NR1H2NR1H3TSHRALDH1A1CRHBP | |
| SCHEMBL8228982 | 0.82 | CYP2C19 (0.68) | NR1H2NR1H3TSHRALDH1A1CRHBP | |
| Nitrogen SCHEMBL4600396 | 0.81 | CRHBP (0.58) | NR1H2NR1H3TSHRALDH1A1CRHBP | |
| SCHEMBL12844706 | 0.81 | HDAC1 (0.48) | TSHRHTTL3MBTL1ALDH1A1PYCR1 | |
| SCHEMBL10054994 | 0.81 | CRHBP (0.67) | NR1H2NR1H3TSHRHTTL3MBTL1 | |
| SCHEMBL8263076 | 0.80 | NR1H2 (0.54) | NR1H2NR1H3TSHRALDH1A1CRHBP | |
| SCHEMBL17602279 | 0.80 | NR1H2 (0.58) | NR1H2NR1H3TSHRALDH1A1CRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818576-B | Secondary amine derivative synthesized by rare earth catalysis and preparation method thereof | 温州大学 | 2023-02-24 | — | — | CN | disclosed |
| CN-113473975-A | Process for preparing functionalized cyclooctenes | 坦博公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-110818576-A | Secondary amine derivative synthesized by rare earth catalysis and preparation method thereof | 温州大学 | 2020-02-21 | — | — | CN | disclosed |
| CN-106748805-B | A kind of alkylation of amine | 上海科技大学 | 2019-03-19 | — | — | CN | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| CN-1520298-A | Pyrazolopyrimidines as therapeutic agents | �����ʩ���عɷݹ�˾ | 2004-08-11 | — | — | CN | disclosed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| CN-1390219-A | Pyrazolopyrimidines as therapeutic agents | ABBOTT AG (DE) | 2003-01-08 | — | — | CN | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | NR1H2 2929/4885NR1H3 3437/4885TSHR 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.